Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    AZD9833

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Delays Ruling on AstraZeneca Breast Cancer Drug
    FDA Delays Ruling on AstraZeneca Breast Cancer Drug

    27 May 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/biotech/fda-delays-ruling-astrazenecas-breast-cancer-drug-after-negative-adcomm-vote

    FIERCE PHARMA
    27 May 2026
    Share Share
    Astrazeneca Breast Cancer Drug Fails FDA Advisory Committee
    Astrazeneca Breast Cancer Drug Fails FDA Advisory Committee

    01 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/astrazenecas-breast-cancer-drug-fails-to-earn-backing-of-fda-advisory-committee

    BIOSPACE
    01 May 2026
    Share Share
    FDA Panel Rejects AstraZeneca Oral SERD Over Insufficient OS Data
    FDA Panel Rejects AstraZeneca Oral SERD Over Insufficient OS Data

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257143

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    AstraZeneca Faces Uphill Adcomm Battle Amid FDA Questions
    AstraZeneca Faces Uphill Adcomm Battle Amid FDA Questions

    29 Apr 2026

    // BIOSPACE

    https://www.biospace.com/fda/astrazeneca-faces-uphill-battle-at-upcoming-adcomm-in-face-of-fda-questions

    BIOSPACE
    29 Apr 2026
    Share Share
    Astrazeneca Drugs Face FDA Cancer Advisory Panel After 9 Months
    Astrazeneca Drugs Face FDA Cancer Advisory Panel After 9 Months

    09 Mar 2026

    // BIOSPACE

    https://www.biospace.com/fda/two-astrazeneca-drugs-to-be-scrutinized-in-first-fda-cancer-advisory-panel-in-9-months

    BIOSPACE
    09 Mar 2026
    Share Share
    SERENA-6 Trial Shows Guardant360 CDx Test Value in Breast Cancer
    SERENA-6 Trial Shows Guardant360 CDx Test Value in Breast Cancer

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602107458/en/SERENA-6-Phase-III-Trial-Demonstrates-Clinical-Value-of-Guardant360-CDx-Test-to-Detect-Emergence-of-Endocrine-Resistance-and-Inform-a-Switch-in-Therapy-Before-Radiological-Disease-Progression-in-Advanced-Breast-Cancer

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.